Good play on a speculative migraine pain management device. Around 600 M shares outstanding with low float and virtually no debt.
A small investment in ADHC could yield exponential returns in a few short years. Market cap could exceed to over 11B+ with successful FDA and clinical studies then successful marketplace execution.
Over $1 PPS is not unreasonable with this massive pain management market.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.